Home » Stocks » SDGR

Schrodinger, Inc. (SDGR)

Stock Price: $90.89 USD -1.96 (-2.11%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $89.43 -1.46 (-1.61%) Jan 15, 7:59 PM
Market Cap 6.32B
Revenue (ttm) 100.90M
Net Income (ttm) -20.09M
Shares Out 66.34M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $90.89
Previous Close $92.85
Change ($) -1.96
Change (%) -2.11%
Day's Open 92.20
Day's Range 87.61 - 94.50
Day's Volume 793,134
52-Week Range 26.60 - 94.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Invezz - 2 weeks ago

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...

Other stocks mentioned: MORF, OLMA
Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data...

The Motley Fool - 1 month ago

The company announced a partnership with Bristol Myers Squibb.

Market Watch - 1 month ago

Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in ...

Other stocks mentioned: BMY
Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discover...

Other stocks mentioned: BMY
Seeking Alpha - 1 month ago

Schrödinger stock is almost at half the price since peaking in the summer. Stock dilution hurt investors, but the market is betting on its software growth.

Seeking Alpha - 2 months ago

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial ...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that membe...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will pr...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a c...

CNN Business - 2 months ago

Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual...

Other stocks mentioned: CRWD, DDOG, GH, OKTA, U, ZS
Zacks Investment Research - 3 months ago

Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Seeking Alpha - 3 months ago

Schrödinger, Inc. has exhibited a stock price slide since July, even as revenue growth continues above expectations.

The Motley Fool - 4 months ago

Three great performing yet relatively unknown med-tech stocks with a high upside.

Other stocks mentioned: SLP, VEEV
Seeking Alpha - 4 months ago

Schrödinger's computational platform integrates physics-based methods with machine-learning techniques to enable drug discovery and development of novel materials.

Seeking Alpha - 4 months ago

Schrödinger has an innovative computational platform that accelerates the discovery of new molecules for use in therapeutics and industrial materials.

Zacks Investment Research - 5 months ago

Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of struct...

GuruFocus - 7 months ago

A company that can speed up drug discovery; one that is already partnering with the world’s 20 biggest drug companies and appears to be just scratching the surface of its potential.

Seeking Alpha - 8 months ago

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Schrodinger - Taking Drug Discovery To The 'Space Age'

The Motley Fool - 10 months ago

The company continues to coast on a positive note from Citron Research.

The Motley Fool - 10 months ago

1 hot IPO plus 1 comparison to Tesla equals 1/3 more stock value.

Benzinga - 10 months ago

Notable activist short seller Andrew Left and his Citron Research firm said in a new report Schrodinger Inc (NASDAQ: SDGR) is the "most important IPO" in the past five years.

The Motley Fool - 11 months ago

This IPO has been a success regardless.

About SDGR

Schrödinger provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computat... [Read more...]

Industry
Health Information Services
IPO Date
Feb 6, 2020
CEO
Dr. Ramy Farid
Employees
392
Stock Exchange
NASDAQ
Ticker Symbol
SDGR
Full Company Profile

Financial Performance

In 2019, Schrodinger's revenue was $85.54 million, an increase of 28.37% compared to the previous year's $66.64 million. Losses were -$24.57 million, -13.56% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 91.00, which is an increase of 0.12% from the latest price.

Price Target
$91.00
(0.12% upside)
Analyst Consensus: Buy